Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.

Autor: Zamani, Parvin1,2 (AUTHOR), Mashreghi, Mohammad1,2 (AUTHOR), Rezazade Bazaz, Mahere1,3 (AUTHOR), Zargari, Selma4 (AUTHOR), Alizadeh, Farzaneh4 (AUTHOR), Dorrigiv, Mahyar2 (AUTHOR), Abdoli, Asghar5,6 (AUTHOR), Aminianfar, Hossein7,8 (AUTHOR), Hatamipour, Mahdi1 (AUTHOR), Zarqi, Javad1 (AUTHOR), Behboodifar, Saeed1 (AUTHOR), Samsami, Yalda4 (AUTHOR), Khorshid Sokhangouy, Saeideh4 (AUTHOR), Sefidbakht, Yahya9 (AUTHOR), Uskoković, Vuk10 (AUTHOR), Rezayat, Seyed Mahdi11 (AUTHOR), Jaafari, Mahmoud Reza1,2 (AUTHOR) Jafarimr@mums.ac.ir, Mozaffari-Jovin, Sina1,4,12 (AUTHOR) Mozaffaris@mums.ac.ir
Zdroj: Journal of Controlled Release. Aug2023, Vol. 360, p316-334. 19p.
Databáze: Academic Search Ultimate
Externí odkaz: